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Summary Purpose The therapeutic index of proteasome in-
hibitors may be improved through selective inhibition of a
sub-component of the ubiquitin-proteasome system, such as
the NEDD8-conjugation pathway. This multicenter, phase I,
dose-escalation study assessed safety and the maximum toler-
ated dose (MTD), pharmacokinetics, pharmacodynamics, and
antitumor activity of pevonedistat, an investigational
NEDD8-activating enzyme (NAE) inhibitor, in patients
with metastatic melanoma.Methods Patients received intrave-
nous pevonedistat on Days 1, 4, 8, 11 (schedule A) or 1, 8, 15
(schedule B) of 21-day cycles. Results 26 patients received
pevonedistat 50–278 mg/m2 on schedule A; 11 patients re-
ceived pevonedistat 157 mg/m2 on schedule B. The schedule
A MTD was 209 mg/m2: dose-limiting toxicities (DLTs) in-
cluded grade 3 hypophosphatemia and grade 3 increased
blood creatinine (associated with grade 3 hyperbilirubinemia).
Two schedule A patients experienced acute organ failure tox-
icities, one of whom experienced grade 5 acute renal failure.
Dose escalation did not occur in schedule B: DLTs included
grade 3 myocarditis, grade 2 acute renal failure, and
grade 2 hyperbilirubinemia in a single patient. Pevonedistat
pharmacokinetics were approximately dose-proportional
across the dose range studied, with a biphasic disposition pro-
file characterized by a short elimination half-life (~10 h).
Pharmacodynamic studies showed increases in NAE-
regulated transcripts post-treatment; all post-dose biopsy sam-
ples were positive for pevonedistat-NEDD8 adduct. One
schedule A patient achieved a partial response; 15 patients
had stable disease (4 lasting ≥6.5 months). Conclusions
Pevonedistat was generally well tolerated at the MTD.
Anticipated pharmacodynamic effects of NAE inhibition were
observed with single-agent pevonedistat in peripheral blood
and tumor tissue.
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Introduction
The ubiquitin–proteasome system (UPS) plays a critical role
in regulating intracellular proteins in eukaryotic cells, includ-
ing key substrate proteins that mediate cell growth and surviv-
al, cellular signaling, and transcription factor regulation [1].
Dysregulation of the UPS has been implicated in cancer de-
velopment and progression [2]. The clinical success of protea-
some inhibitors such as bortezomib and carfilzomib has vali-
dated the UPS as a rational target for cancer therapy [3].
However, these proteasome inhibitors result in broad inhibi-
tion of protein degradation, which accounts for their toxic
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effects. The therapeutic index of proteasome inhibitors may be
improved through selective inhibition of a sub-component of
the UPS, such as the neddylation pathway, as described below.
The UPS regulates degradation of intracellular proteins by
tagging substrate proteins with a polyubiquitin chain, which
marks them for subsequent degradation by the proteasome [4].
The polyubiquitination process is mediated by E3 ligases.
Cullin-RING ligases (CRLs), a subgroup of the E3 ligases,
are especially important in the degradation of several proteins
relevant to oncology, including the cyclin-dependent kinase
inhibitor p27, Cdt1 (chromatin licensing and DNA replication
factor-1), and Nrf-2 [nuclear factor (erythroid derived 2)-re-
lated factor 2] [5]. CRLs are activated via the neddylation
pathway [6], which involves conjugation of the ubiquitin-
like protein NEDD8 (neural precursor cell expressed, devel-
opmentally down-regulated 8) to the CRLs. NEDD8 conjuga-
tion is essential for the E3 ligase activity of CRLs [5].
The NEDD8-activating enzyme (NAE) is a critical regula-
tor of the neddylation pathway [6]. Inhibition of NAE can
inhibit the activity of the CRLs and result in accumulation of
CRL substrate proteins [5, 6]. Pevonedistat (TAK-924/
MLN4924) is a first-in-class, investigational, small-molecule
inhibitor of NAE [7]. It forms a covalently bound adduct with
NEDD8 while bound to NAE [8]. NAE inhibition via
pevonedistat prevents the proteasomal degradation of a frac-
tion (~20 %) of the proteins regulated by the UPS, in contrast
to the broad inhibition seen with proteasome inhibitors [5–7,
9, 10]. This fraction includes several proteins involved in tu-
morigenesis, such as the tumor suppressor ICER [11], and
proteins involved in the modulation of transcription, cell cycle
control, and apoptosis, such as ING3 [12].
There are extensive preclinical data supporting the poten-
tial utility of pevonedistat in melanoma. Pevonedistat is cyto-
toxic in a range of hematologic and solid tumor cell lines [10,
13–18], and has shown antitumor activity in a number of in-
vivo models [15, 16, 19, 20]. The mechanism of action pri-
marily involves stabilization of Cdt1 and induction of the
DNA damage response [9, 13, 21, 22], but likely also includes
autophagy [14, 23] and inhibition of nuclear factor-κB
through stabilization of I-κBα [16, 19]. Dysregulation of the
UPS has been implicated in the development and progression
of melanoma [11, 12]; thus, pevonedistat has been investigat-
ed in preclinical studies in melanoma cell lines and tumor
xenograft models, and has demonstrated cytotoxicity and an-
titumor activity [24–28]. Pevonedistat-mediated cell death in
melanoma cell lines appears to involve inhibition of cellular
phase transition following the induction of DNA re-
replication stress [24]. Pevonedistat was associated with tu-
mor growth inhibition and regression in patient-derived mel-
anoma tumor mouse xenograft explant models [27].
Preliminary clinical activity of pevonedistat in melanoma
was also noted in the first-in-human phase I study; in nine
melanoma patients, one achieved a partial response and
another achieved stable disease lasting 6 months [29].
Investigation in melanoma patients also offered the feasibility
of repeated skin tumor biopsies to facilitate pharmacodynamic
(PD) investigations.
This phase I study (NCT01011530) was conducted to as-
sess the safety, pharmacokinetics (PK), PD, and antitumor
activity of pevonedistat in patients with metastatic mel-
anoma. The study tested two administration schedules of
pevonedistat. Paired pre-dose and post-dose tumor biopsies
were acquired in patients treated at the maximum tolerated
dose (MTD) to evaluate the PD effects of NAE inhibition in
this clinical setting. The study results have helped inform the
overall clinical development of pevonedistat.
Patients and methods
Patients
Eligible patients were ≥18 years old, and had a diagnosis of
metastatic melanoma, an Eastern Cooperative Oncology Group
(ECOG) performance status of 0–2, adequate hematologic, he-
patic, renal, and cardiovascular function, and radiographically
or clinically evaluable tumor. Patients enrolled in the expansion
cohort required measurable disease as defined by the Response
Evaluation Criteria in Solid Tumors (RECIST) criteria (v1.1).
Patients with brain metastases were eligible if they were
asymptomatic and had stable neurologic status for ≥2 weeks
after completion of local therapy (surgery or radiation).
Patients were excluded if they had received radiotherapy,
systemic antineoplastic therapy, investigational agents,
CYP3A inhibitors/inducers, major surgery, serious infection,
or antibiotic therapy within 14 days of first dose of
pevonedistat. Patients with knownHIVor hepatitis B infection
or known/suspected active hepatitis C infection were exclud-
ed, as were patients with a history of coagulopathy or bleeding
disorder. The study was conducted in accordance with the
ethical principles originating in or derived from the
Declaration of Helsinki and its amendments and in accordance
with 21 Code of Federal Regulations 50 / 56 / 312.
Institutional review boards at each of the participating inves-
tigational centers approved the study. All patients provided
written informed consent.
Study design
This was an open-label, multicenter, phase I dose-escalation
study. The primary objectives were to determine the safety
profile, establish the MTD, and inform the recommended
phase II dose and dosing schedule for pevonedistat.
Secondary objectives were to evaluate the PK and antitumor
activity of pevonedistat, and to investigate its PD effects in
blood and tumor samples.
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Patients received pevonedistat as 1 h intravenous infusions
either on Days 1, 4, 8, and 11 (schedule A) or on Days 1, 8,
and 15 (schedule B, weekly dosing) of 21-day cycles. For
schedule A, intermittent dosing on Days 1, 4, 8, and 11 was
chosen to match the twice-weekly schedule of the proteasome
inhibitor bortezomib [30]. The starting dose of 50 mg/m2 was
selected based on the toxicities and the MTD observed in
another phase I study that investigated pevonedistat adminis-
tration on Days 1–5 of 21-day cycles in patients with ad-
vanced solid tumors. It was hypothesized that intermittent
dosing – extending the dose over a 2-week period – would
be better tolerated than the continuous dosing schedule, which
was associated with severe hepatotoxicity [29]. Schedule B,
which was added subsequently through a protocol amend-
ment, was based on the rationale that weekly bortezomib has
similar efficacy and is more convenient than the twice-weekly
schedule [31, 32]. The starting dose for weekly dosing of
pevonedistat on schedule B (157 mg/m2) was based on data
indicating that this dose was well tolerated on a Day 1, 4, 8,
and 11 schedule in a phase I study in multiple myeloma and
lymphoma [33]. Patients could receive pevonedistat until dis-
ease progression or unacceptable drug-related toxicity, up to a
maximum of 12 months.
Dose escalation proceeded via a Bayesian continual reas-
sessment method using 2-patient cohorts and 1.33-fold dose
increments over the previous dose level. Dose escalation de-
cisions were based on occurrence of DLTs in Cycle 1 and the
predicted MTD from the continual reassessment model
(Supplementary Fig. S1). The MTD was defined as the dose
level at which 6 patients had been treated and at which the
algorithm did not recommend dose de-escalation. Additional
patients were to be enrolled at the MTD to further evaluate
safety.
DLTs were defined as: grade 4 neutropenia for >7 consec-
utive days or grade 3 neutropenia with fever (oral temperature
≥38.5 °C) and/or infection; grade 4 thrombocytopenia for >7
consecutive days, platelets <10,000/mm3 at any time, or grade
3 thrombocytopenia with bleeding; grade ≥3 nausea or diar-
rhea despite optimal anti-emetic prophylaxis or supportive
therapy, or any other grade ≥3 nonhematologic toxicity (ex-
cept arthralgia/myalgia, brief [<1 week] fatigue, or fever oc-
curring in the absence of grade ≥3 neutropenia); a decrease in
LVEF to <40 % or an absolute reduction of ≥10 % to <50 %;
an increase in pulmonary artery systolic pressure, as deter-
mined by echocardiogram, to >50 mmHg or three times that
at baseline; treatment delay of >1week due to lack of recovery
from drug-related toxicities, or other drug-related toxicity re-
quiring doses to be missed or therapy to be discontinued.
Assessments
Adverse events (AEs) were graded using the National Cancer
Institute’s Common Terminology Criteria for AEs version 3.0.
Response was assessed using the modified RECIST guideline
(v1.1) [34]. Computed tomography or magnetic resonance
imaging scans were performed at screening, at the end of
Cycle 2, and then every other cycle.
Blood samples (3 mL) for PK analysis were collected dur-
ing Cycle 1. On schedule A, serial samples were collected
within 1 h before dosing on Day 1, immediately after comple-
tion of infusion (immediately before switching off infusion
pump), and at 1, 4, and 7 h after completion of infusion.
Samples were also collected on Days 2 and 3; on Days 4
and 8 (immediately before dosing and immediately after com-
pletion of infusion); on Day 11 immediately before dosing,
immediately after completion of infusion, and at 4 and 7 h
after completion of infusion; and on Day 15. On schedule B,
blood samples were collected within 1 h before dosing on Day
1, immediately after completion of infusion (immediately be-
fore switching off infusion pump), and at 1, 2, 4, and 7 h after
completion of infusion. Samples were also collected on Days
2, 3, and 4; and on Days 8 and 15 (immediately before dosing
and immediately after completion of infusion). Samples were
analyzed at Tandem Labs (West Trenton, NJ) for pevonedistat
plasma concentrations using Good Laboratory Practice-
validated liquid chromatography/tandem mass spectrometry
methods. The dynamic ranges were 1–500 ng/mL for the
low-range assay and 75–7500 ng/mL for the high-range assay.
Blood samples for PD analysis were collected during Cycle
1. On schedule A samples were collected: at screening; on
Days 1 and 11 within 1 h before dosing and at 4 and 7 h after
completion of infusion; and on Days 4 and 15. On schedule B
samples were collected: at screening; on Day 1 within 1 h
before dosing and 1, 2, 4, and 8 h after completion of infusion;
on Day 8 within 1 h before dosing; and on Day 15 within 1 h
before dosing and 1, 2, and 4 h after completion of infusion.
Gene expression of NAE-regulated transcriptional tar-
gets (ATF3, GCLM, GSR, MAG1, NQ01, SLC7A11,
SRXN1, and TXNRD1) in whole blood was analyzed
by reverse-transcription polymerase chain reaction (RT-
PCR). Raw data were transformed prior to calculation
of percent change and assumptions were made for miss-
ing data, as previously described [33]. Summary statistics
were generated for the percent change from baseline at each
time point for each gene.
For patients in the MTD expansion cohort, paired
tumor biopsies were obtained at screening and at 3–
6 h post-dosing on Day 4 (schedule A) or Day 8
(schedule B). Immunohistochemistry was used to detect
pevonedistat–NEDD8 adduct (to demonstrate penetration
of the drug into tumor tissue and the formation of the
expected entity upon NAE inhibition), and to determine levels
of Cdt1 and Nrf-2 expression (to demonstrate anticipated PD
effects arising from NAE inhibition). Immunohistochemical
analyses were performed at Millennium Pharmaceuticals, Inc.
as previously described [33].
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Statistics
All results were summarized descriptively, and no formal hy-
pothesis testing was conducted. The safety population includ-
ed all patients who received ≥1 dose of pevonedistat. The
DLT-evaluable population comprised patients who received
all scheduled doses during Cycle 1 or experienced a DLT
during Cycle 1. The PK-evaluable population included all
patients who received all protocol-defined doses in Cycle 1,
had sufficient plasma concentration–time data to reliably esti-
mate PK parameters, and had not received any excluded con-
comitant medications per protocol. Individual pevonedistat
plasma concentration–time data were analyzed by
noncompartmental methods using WinNonlin software
(Version 6.2, Pharsight Corporation, Cary, NC). Plasma con-
centrations below the lower limit of quantification were set to
zero for analysis. The response-evaluable population included
all patients who received ≥1 dose of pevonedistat, had mea-




A total of 37 patients were enrolled and received at least one
dose of pevonedistat at one of three sites in the United States
from December 2009 to May 2012. Twenty six patients re-
ceived pevonedistat on schedule A and 11 patients received
pevonedistat on schedule B. Patients’ baseline demographics
and disease characteristics are summarized in Table 1. Thirty
one (84 %) patients had skin melanoma as the primary site. Of
the 15 patients whose tumor could be assessed for BRAF mu-
tation status, 10 (67 %) patients had wild-type BRAF, and 5
(33 %) patients had a BRAF V600E mutation.
All patients had discontinued pevonedistat at the time of
data cut-off. On schedule A, 21 (81%) patients came off study
upon experiencing progressive disease (n=20) or symptom-
atic deterioration (n= 1); the remaining 5 (19 %) patients
discontinued treatment due to AEs (n = 2), withdrawal
(n=2), and lengthy treatment hold unrelated to study drug
(n=1). On schedule B, 8 (73 %) patients came off study upon
experiencing progressive disease, and 3 (27 %) patients
discontinued due to AEs (n=2) or withdrawal (n=1).
Dose escalation, DLTs, and MTD determination
On schedule A, 26 patients received pevonedistat at one of 7
different dose levels, including 2 patients each at 50, 67, and
89 mg/m2, 5 at 118 mg/m2, 2 at 157 mg/m2, 11 at 209 mg/m2,
and 2 at 278 mg/m2. A total of 19 patients were DLT-
evaluable. NoDLTs were reported at the first three dose levels.
At the 118 mg/m2 dose level, one patient experienced asymp-
tomatic drug-related grade 3 hypophosphatemia on Day 4 of
Cycle 1, which resulted in a dose reduction to 89 mg/m2; the
hypophosphatemia did not recur at the lower dose. A total of 5
patients were enrolled at 118 mg/m2 and no other DLTs were
recorded. One patient at the 118 mg/m2 dose level was hospi-
talized on Day 3 of Cycle 1 due to grade 3 acute respiratory
failure, which resolved on Day 5; this patient resumed
pevonedistat at a reduced dose of 89 mg/m2 and tolerated it
well. Although the investigator did not initially report this as a
DLT, attributing it to underlying lung metastases, it was even-
tually concluded that this event had met the protocol-specified
definition of a DLT. Subsequently, no DLTs were reported at
the 157 or 209 mg/m2 dose levels. At the 278 mg/m2 dose
level, one patient experienced drug-related grade 3 increased
blood creatinine and grade 3 increased blood bilirubin on Day
3 of Cycle 1, which resulted in hospitalization and treatment
discontinuation. These events subsequently resolved without
long-term sequelae. No further patients were enrolled at
278 mg/m2 due to the severity of the DLT at this dose level.
Four additional patients were enrolled at the 209 mg/m2 dose
level. In the absence of any recorded DLTs among the initial 6
patients enrolled at this dose level, the MTD of pevonedistat
on schedule Awas determined to be 209 mg/m2, and another 5
patients were enrolled to further evaluate safety. Among these
5 dose-expansion patients, two experienced AEs that met the
definition for DLTs; both patients had dose reductions to
157 mg/m2. One patient had drug-related grade 1 increased
aspartate aminotransferase, and one patient had drug-related
grade 1 increased B-type natriuretic peptide. Additionally, one
dose-expansion patient with a history of renal insufficiency
was hospitalized on Day 2 of Cycle 1 due to grade 4 acute
renal failure and grade 4 acute hepatic failure, and subsequent-
ly died on day 9 due to acute renal failure.
On schedule B, all 11 patients received pevonedistat at the
157 mg/m2 dose level. Dose escalation did not occur due to
the Sponsor’s decision to stop enrollment following a
program-wide review. Ten patients were DLT-evaluable. One
patient experienced DLTs of grade 3 myocarditis on Day 1,
and grade 2 acute renal failure and grade 2 hyperbilirubinemia
on Day 2 of Cycle 1, which resulted in hospitalization and
treatment discontinuation. The exact cause of these
DLTs was unclear, but was thought to be secondary to direct
effects of pevonedistat on the kidneys, biliary tree, and
myocardium.
Pevonedistat exposure and safety profile
All 37 patients received at least one dose of pevonedistat and
were included in the safety population. The median number of
treatment cycles of pevonedistat administered was 2 (range 1–
16) for the entire study population, with a median of 4 (range
1–16) on schedule A and a median of 2 (range 1–11) on
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schedule B. The intensity of pevonedistat dosing, defined as
the dose received as a proportion of the dose expected, was
≥80 % in 19 (73 %) patients on schedule A and 8 (73 %)
patients on schedule B.
The safety profile of pevonedistat is summarized in
Table 2. All patients experienced at least one AE. The most
common AEs regardless of causality are shown in
Supplementary Table S2 and included fatigue (n = 25;
68%), diarrhea (n=18; 49%), anemia (n=15; 41%), myalgia
(n=15; 41 %), nausea (n=13; 35 %), constipation (n=12;
32 %), vomiting (n=12; 32 %), arthralgia (n=11; 30 %),
decreased appetite (n=11; 30 %), dizziness (n=10; 27 %),
and peripheral neuropathy (n=10; 27 %). Peripheral neurop-
athy was mild (grade 1) in all 10 patients; due to a lack of
comprehensive data on prior therapies, we could not address
the possibility that prior treatment with neurotoxic agents
(such as taxanes, platinum-based therapies, or vinca alkaloids)
predisposed these patients to develop neuropathy with
pevonedistat. Common drug-related AEs are listed in
Table 2. Overall, 18 (49 %) patients experienced grade ≥3
AEs; the only grade ≥3 AEs, regardless of causality, that were
reported in more than one patient were anemia (n=5; 14 %),
benign/malignant neoplasms, and small intestinal obstruction
(each n=2; 5 %) (Supplementary Table S2). Grade ≥3 AEs
assessed as drug-related by the investigators are shown in
Table 2.
Overall, 14 (38 %) patients experienced at least one serious
AE (SAE), with 6 (16 %) experiencing at least one drug-
related SAE. Four (11 %) patients had AEs that resulted in
discontinuation: a patient receiving pevonedistat 209 mg/m2
on schedule A had drug-related grade 4 acute renal failure; a
patient receiving pevonedistat 278 mg/m2 on schedule A
discontinued due to the DLTof drug-related grade 3 increased
blood creatinine and drug-related grade 3 increased blood bil-
irubin; a patient receiving pevonedistat 157 mg/m2 on sched-
ule B discontinued due to grade 3 small intestinal obstruction
(associated with multifocal abdominal subcutaneous metasta-
tic deposits), which was considered unrelated to treatment; a
second patient on schedule B discontinued due to the DLTs of
grade 3 myocarditis, grade 2 acute renal failure, and grade 2
hyperbilirubinemia.
Three patients died on study, within 30 days of their last
dose of pevonedistat. One patient treated at 118 mg/m2 on
schedule A received four doses of pevonedistat, discontinued









Median age, years (range) 62.9 (34–79) 57.8 (33–76) 61.8 (33–79)
Male, n (%) 16 (62) 7 (64) 23 (62)
Race, n (%)
White 26 (100) 10 (91) 36 (97)
Asian 0 1 (9) 1 (3)
ECOG performance status, n (%)
0 13 (50) 2 (18) 15 (41)
1 13 (50) 9 (82) 22 (59)
Primary site, n (%)
Melanoma of the skin 22 (85) 9 (82) 31 (84)
Other melanoma* 4 (15) 2 (18) 6 (16)
Disease Stage, n (%)
III (unresectable) 5 (19) 3 (27) 8 (22)
IV 16 (62) 8 (73) 24 (65)
Not available 5 (19) 0 5 (14)
LDH>ULN, n (%)† 12 (48) 7 (70) 19 (54)
>2 x ULN, n (%) 3 (12) 3 (30) 6 (17)
Prior therapy, n (%)
Prior antineoplastic therapy 25 (96) 11 (100) 36 (97)
Prior radiation 18 (69) 10 (91) 28 (76)
Prior surgery or non-radiation procedure 25 (96) 9 (82) 34 (92)
*M1c melanoma ocular, malignant melanoma of the conjunctiva, malignant melanoma of the uvea, melanoma –
left ear, nasal melanoma, ocular choroidal melanoma, each n = 1. †N= 35; LDH data not available at baseline in 2
patients, 1 in each schedule
ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, ULN upper limit of normal
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due to symptomatic deterioration not related to treatment, and
died 26 days after the Cycle 1, Day 11 dose. A patient treated
at 209 mg/m2 on schedule A received one dose of
pevonedistat and died due to drug-related acute renal failure
on Day 9 of Cycle 1. One patient on schedule B died 30 days
after the Cycle 2, Day 15 dose due to progressive disease.
Pharmacokinetics
A total of 34 patients were evaluable for PK, including 24
patients on schedule A (2 patients each treated at pevonedistat
50 and 67mg/m2, 1 at 89mg/m2, 5 at 118mg/m2, 1 at 157mg/
m2, 11 at 209 mg/m2, and 2 at 278 mg/m2) and 10 on schedule
B. Mean pevonedistat plasma concentration–time profiles on
Cycle 1, Day 1 for all patients are shown in Fig. 1. On sched-
ule A, the majority of individual PK profiles were truncated at
the 7-h post-infusion time point due to missing subsequent
samples. Therefore, pevonedistat systemic exposure (as
assessed by area under the plasma concentration–time curve
[AUC]) could not be accurately estimated, except at theMTD.
Based on limited data availability in both schedules, mean
plasma exposure of pevonedistat (maximum plasma con-
centration or AUC when available) increased approxi-
mately proportionally with dose from 50 to 278 mg/m2
after Day 1 intravenous infusion. Individual PK profiles
across schedules A and B showed a biphasic disposition
phase following completion of the intravenous infusion.
Plasma concentrations were generally quantifiable be-
tween 24 and 72 h after dosing across the dose range
studied. Pevonedistat PK parameters at the schedule A
MTD of 209 mg/m2 and at 157 mg/m2 on schedule B
are summarized in Table 3.
Table 2 Safety profile of
pevonedistat, including drug-
related AEs reported in at least
10 % of patients overall, and all
drug-related grade ≥3 AEs
AE, n (%) Schedule A (n= 26) Schedule B (n= 11) Total (N= 37)
Any AE 26 (100) 11 (100) 37 (100)
Any drug-related AE 25 (96) 10 (91) 35 (95)
Common drug-related AE (≥10 % of patients):
Fatigue 12 (46) 6 (55) 18 (49)
Myalgia 10 (38) 4 (36) 14 (38)
Diarrhea 10 (38) 2 (18) 12 (32)
Nausea 8 (31) 3 (27) 11 (30)
Anemia 6 (23) 4 (36) 10 (27)
Peripheral neuropathy 7 (27) 3 (27) 10 (27)
Vomiting 6 (23) 3 (27) 9 (24)
Arthralgia 4 (15) 2 (18) 6 (16)
Decreased appetite 5 (19) 1 (9) 6 (16)
Pyrexia 4 (15) 1 (9) 5 (14)
AST increased 5 (19) 0 5 (14)
GGT increased 5 (19) 0 5 (14)
Blood ALP increased 5 (19) 0 5 (14)
Chills 3 (12) 1 (9) 4 (11)
ALT increased 4 (15) 0 4 (11)
Night sweats 3 (12) 1 (9) 4 (11)
Any grade ≥3 AE 12 (46) 6 (55) 18 (49)
Any drug-related grade ≥3 AE 7 (27) 4 (36) 11 (30)
Drug-related grade ≥3 AEs (>1 patient)*:
Anemia 1 (4) 1 (9) 2 (5)
Any serious AE 9 (35) 5 (45) 14 (38)
Any drug-related serious AE 5 (19) 1 (9) 6 (16)
AE resulting in study drug discontinuation 2 (8) 2 (18) 4 (11)
On-study death 2 (8) 1 (9) 3 (8)
*The following drug-related grade ≥3 AEs were reported in 1 patient each: acute hepatic failure, acute renal
failure, acute respiratory failure, angina pectoris, anuria, arthralgia, blood bilirubin increased, blood creatinine
increased, confusional state, dyspnea exertional, fatigue, hepatic encephalopathy, hyponatremia,
hypophosphatemia, hypotension, myocarditis, respiratory distress, respiratory failure, and syncope
AE adverse events, ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase,
GGT gamma-glutamyltransferase
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Pharmacodynamics
A panel of NAE-regulated transcripts was measured (by RT-
PCR) in whole blood samples collected on study. All eight
NAE-regulated gene transcripts were significantly increased
post-treatment among patients receiving pevonedistat at the
MTD on schedule A and patients receiving pevonedistat on
schedule B (Supplementary Fig. S2, Supplementary Table S1).
Induction of all NAE-regulated transcriptional targets was ob-
served at pevonedistat doses of 50 mg/m2 and higher (data not
shown). On schedule A, changes were characterized by rapid
increases in gene transcript levels that remained increased
compared with baseline during the first 7 h following
pevonedistat dosing on Days 1 and 11, when assessments were
conducted. Changes were heterogeneous between patients at a
given dose level and between gene transcripts at a given dose
level, as shown for the pevonedistat MTD of 209 mg/m2 in
Supplementary Figure S2. SLC7A11 and NQ01 were
consistently the most robustly increased gene transcripts.
Findings were similar on schedule B (Supplementary Fig. S2).
Tumor biopsies were collected at screening and at 3–6 h
after the Cycle 1, Day 4 dose of pevonedistat from 3 patients
in the Schedule A MTD expansion cohort. All of the Day 4
post-dose biopsy samples were positive for the pevonedistat–
NEDD8 adduct, demonstrating penetration of pevonedistat
into the tumors. Additionally, in one patient with adequate
biopsy tissue, it was feasible to analyze the immunohisto-
chemical expression of Cdt1 and Nrf-2, both of which are
substrates of CRLs; expression of both proteins was increased
post-treatment (Fig. 2).
Clinical activity
Thirty-one of 37 patients were evaluable for response, includ-
ing 23 in schedule A and 8 in schedule B. Figure 3 indicates
the duration of pevonedistat exposure among all 37 patients
across both schedules, and highlights the patients who
achieved best responses of partial response or stable disease.
These included one (3 %) partial response, achieved by a
patient on schedule A who received pevonedistat at the
MTD (209 mg/m2). Another 15 (48 %) patients on schedule
A and B had a best response of stable disease; the remaining
15 (48 %) patients had progressive disease.
The patient who achieved a partial response was a 61-year-
old white female with stage IV malignant melanoma (tumor
sites in the brain, lung, and skin). She had received prior anti-
neoplastic therapy (tremelimumab), radiation therapy, and sur-
gery, and received 6 cycles of pevonedistat 209 mg/m2. The
partial response was reported at Cycle 4 (Supplementary
Fig. S3 includes PET scans showing tumor reduction) and
was maintained until an assessment of progressive disease af-
ter Cycle 6, which resulted in discontinuation of study treat-
ment. The duration of response was 1.55 months, and the
overall duration of stable disease or better was 4.4 months.
Among the 15 patients who achieved stable disease, 4 had
stable disease for 6.5 months or longer (Fig. 3); none of these
4 patients had a BRAF V600E mutation.
Discussion
This phase I study investigated the safety of two different
administration schedules of pevonedistat, a first-in-class
NAE inhibitor, in patients with metastatic melanoma. The
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Fig. 1 Mean pevonedistat plasma concentration–time profiles on Cycle
1, Day 1 following 1-h intravenous infusion of pevonedistat in patients
receiving different dose levels on schedule A (Days 1, 4, 8, and 11) and
patients receiving the one dose level on schedule B (Days 1, 8, and 15)
Table 3 Pharmacokinetic (PK) parameters of pevonedistat on Cycle 1,
Day 1 in evaluable patients administered pevonedistat via a 1-h infusion
on schedule A (Days 1, 4, 8, and 11) and on schedule B (Days 1, 8, and 15)
Parameter* Schedule A MTD,
209 mg/m2 (n = 11)
Schedule B,
157 mg/m2 (n= 10)
Cmax, ng/mL 3591 (41) 2452 (17)**
Tmax, h
† 1.00 (0.98–1.2) 1.00 (0.92–1.7)**









*Geometric mean (% coefficient of variance) except where indicated.
†Median (range). ‡Arithmetic mean (standard deviation). # n = 8.
¶ n= 5. § n = 1. **n= 9. ‡‡ n= 4. ## n = 3
AUC24hr/AUCinf area under the plasma concentration–time curve from time
0 to 24 h / extrapolated to infinity, CLp systemic (plasma) clearance, Cmax
observed maximum plasma concentration, Tmax time to Cmax, t½ terminal
disposition phase half-life, Vss volume of distribution at steady state
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PD profile of pevonedistat in these patients. NAE inhibition
with pevonedistat resulted in the anticipated PD effects in the
tumor microenvironment in patients with metastatic melano-
ma. These findings, along with data from other phase I studies
of pevonedistat in other solid tumors and hematologic malig-
nancies [29, 33, 35], have helped inform the clinical develop-
ment of this agent, which is ongoing in combination with
azacitidine in patients with acute myeloid leukemia (AML)
(NCT01814826) [36] and in combination with docetaxel,
gemcitabine, and carboplatin–paclitaxel in patients with solid
tumors (NCT01862328). A randomized phase II study of
pevonedistat plus azacitidine versus single-agent azacitidine
in patients with higher risk myelodysplastic syndromes
(MDS), chronic myelomonocytic leukemia, and low blast
AML is currently recruiting patients (NCT02610777).
The pevonedistat MTD achieved in the present study on
schedule A (Days 1, 4, 8, and 11 of 21-day cycles), of 209 mg/
m2, appears similar to the MTD of 196 mg/m2 established
using the same dosing schedule in a study in patients with
multiple myeloma or lymphoma [33]. This contrasts with
the lower MTDs seen with slightly more dose-intensive
schedules in other trials. The MTDs were 110 mg/m2 using
a Day 1, 2, 8, and 9 schedule in patients with multiple mye-
loma or lymphoma [33] and 50–67 mg/m2 using Days 1–5
and Days 1, 3, and 5 schedules in a study in patients with solid
tumors [29]. Of particular note, the MTD of single-agent
pevonedistat was also lower when administered on Days 1,
3, and 5 of 21-day cycles in patients with relapsed/refractory
AML or MDS (50/59 mg/m2; compared with 83 mg/m2 using
a Days 1, 4, 8, and 11 schedule in the same study) [35, 37].
TheMTDwas even lower (20 mg/m2) when pevonedistat was
investigated on the same schedule in combination with
azacitidine in treatment-naïve elderly patients with AML [36].
The reasons for this substantial range in the established
MTDs are not clear, although the lower MTDs were reported
in studies employing more frequent dosing, predominantly on
Days 1, 3, and 5. It is plausible that dosing every other day may
not have allowed sufficient organ recovery time between doses.
This is supported by the safety profile on schedule B (weekly
dosing) in the present study; a dose of 157 mg/m2 resulted in
only 1 DLT in 11 patients. However, the MTDs may also have
been influenced by individual patient- and disease-specific
characteristics and their association with the key pevonedistat-
related toxicities. Thus, comparisons between different studies
in different patient populations should bemadewith caution. Of
note, ongoing studies of pevonedistat in combination are
employing a Days 1, 3, and 5 dosing schedule [36].
The DLTs and other key toxicities observed on schedule A
in the present study, which included hypophosphatemia, acute
renal and hepatic toxicity, and acute respiratory failure, appear
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Fig. 3 Duration of pevonedistat exposure among all 37 patients on
schedules A and B, including the 15 patients achieving stable disease
and the 1 patient achieving a partial response
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toxicities were usually observed soon after the first dose and
did not occur in patients who tolerated the first few
doses well. In the phase I study of pevonedistat in mul-
tiple myeloma and lymphoma, DLTs included febrile
neutropenia, AST elevation, muscle cramps, and throm-
bocytopenia [33]. The phase I study of pevonedistat in
solid tumors reported DLTs of ALT elevation, AST ele-
vation, and hyperbilirubinemia [29]. In the AML/MDS
phase I study, multi-organ failure, reversible ALT eleva-
tion, AST/ALTelevation, cardiac failure, and acute renal fail-
ure were among the reported DLTs [35, 37].
Most patients tolerated pevonedistat well. The precise rea-
sons for the occurrence of acute severe toxicities at higher
pevonedistat doses in a few patients is unclear at this time.
Preclinical studies of mechanism-based toxicity with
pevonedistat showed increased levels of markers of tissue
injury, such as ALT/AST, bilirubin, and creatinine, increased
circulating cytokines, and organ damage in rodents receiving
pevonedistat combined with tumor necrosis factor-alpha [38].
This suggests a mechanism potentially giving rise to the acute
organ failure toxicities reported in the present study and other
phase I studies. Based on a program-wide safety review, doses
of pevonedistat at the higher end of the range studied
(>100 mg/m2) are not being considered for further
investigation.
The limited PK data from this study indicate that plasma
exposure of pevonedistat following completion of the intrave-
nous infusion was approximately dose-proportional across the
50–278 mg/m2 dose range. Pevonedistat showed a biphasic
disposition profile characterized by a short elimination half-
life of approximately 10 h in plasma. These findings are con-
sistent with the PK profile of pevonedistat obtained from other
phase I studies in different tumor types using similar or differ-
ent dosing schedules [29, 33, 35, 37].
PD studies demonstrated the anticipated effects of NAE
inhibition at all doses tested in this study. For example, the
RT-PCR data showing increases in NAE-regulated gene tran-
scripts and the tumor biopsy stains for the CRL substrates
Cdt1 and Nrf-2 are supportive of the mechanism of action of
NAE inhibition and subsequent CRL inactivation. Increases in
these CRL substrates have also been seen in preclinical studies
of pevonedistat [7, 13, 16, 19, 21, 22], and similar PD effects
have been reported from other clinical studies [29, 33, 35–37].
Measurement of NAE-regulated gene transcript levels pro-
vides a simple, indirect way of observing the anticipated
build-up of CRL target proteins as a result of NAE inhibition.
Our findings further validate the use of NAE-regulated tran-
scriptional targets as PD markers of NAE inhibition in the
clinic. The PD studies also confirmed that pevonedistat was
reaching its intended target; immunohistochemical stains of
tumor biopsies indicated that the drug penetrated into the tu-
mor tissue and formed the anticipated pevonedistat–NEDD8
adduct in the presence of activated NAE [8].
The relevance of the efficacy results of this study to the
current therapeutic landscape of metastatic melanoma is un-
clear. At the time of study initiation, there was a substantial
unmet need for novel treatment approaches in this setting, and
the rationale for the investigation of pevonedistat in metastatic
melanoma was supported by preclinical studies showing the
relevance of the mechanism of action, as evidenced by cyto-
toxicity and antitumor activity [24–28]. In the present study, a
partial response was reported in one patient and stable disease
was reported in 15 patients (lasting for 6.5 months ormore in 4
patients). Pevonedistat monotherapy currently has limited util-
ity in the context of the broader melanoma treatment land-
scape, which has evolved rapidly due to the recent emergence
of a number of new therapies, offering improved outcomes
[39]. These new drugs, including ipilimumab (an immune
checkpoint inhibitor targeting CTLA-4) [40], pembrolizumab
and nivolumab (monoclonal antibodies that inhibit the PD-1
receptor) [41, 42], vemurafenib [43] and dabrafenib [44]
(BRAF inhibitors), and trametinib (MEK inhibitor) [45], have
resulted in substantial efficacy and improvements in out-
comes. Pevonedistat, with its good safety profile in most pa-
tients and clinically meaningful antitumor activity in some
patients, may be useful as a combination partner for use with
other melanoma therapies. Interestingly, all of the patients
with a partial response or durable stable disease had wild-
typeBRAFmelanoma. This subgroup ofmelanoma has a clear
unmet need for effective molecularly targeted therapies and
could benefit from further investigation of pevonedistat in
combination with other therapies.
In conclusion, this study has provided further evidence, in
addition to phase I studies in other solid tumors and hemato-
logic malignancies, that NAE inhibition with pevonedistat
results in the anticipated PD effects and that pevonedistat
reaches the tumor target in metastatic melanoma patients.
The data from this study have contributed to the characteriza-
tion of the safety profile of this first-in-class agent, studies of
which are currently ongoing in AML in combination with
azacitidine [36] and in solid tumors in multiple combinations.
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